1. Home
  2. YETI vs NUVB Comparison

YETI vs NUVB Comparison

Compare YETI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo YETI Holdings Inc.

YETI

YETI Holdings Inc.

N/A

Current Price

$36.68

Market Cap

3.3B

ML Signal

N/A

NUVB

Nuvation Bio Inc.

N/A

Current Price

$4.40

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YETI
NUVB
Founded
2006
2018
Country
United States
United States
Employees
N/A
291
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
1.6B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
YETI
NUVB
Price
$36.68
$4.40
Analyst Decision
Buy
Strong Buy
Analyst Count
13
9
Target Price
$47.15
$11.22
AVG Volume (30 Days)
1.5M
4.6M
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.03
N/A
Revenue
$1,868,494,000.00
N/A
Revenue This Year
$9.13
$182.76
Revenue Next Year
$7.16
$91.83
P/E Ratio
$18.58
N/A
Revenue Growth
2.11
N/A
52 Week Low
$26.61
$1.57
52 Week High
$51.29
$9.75

Technical Indicators

Market Signals
Indicator
YETI
NUVB
Relative Strength Index (RSI) 22.10 32.96
Support Level $34.81 $4.04
Resistance Level $39.45 $5.73
Average True Range (ATR) 1.56 0.33
MACD -0.83 -0.05
Stochastic Oscillator 4.96 12.93

Price Performance

Historical Comparison
YETI
NUVB

About YETI YETI Holdings Inc.

YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: